Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity
A large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impact on their quality of life. Anecdotal evidence suggests a beneficial effect of cannabis on spasticity as well as pain. Recently, randomized, double-blind, placebo-controlled studies have confirmed th...
Main Authors: | Verena Isabell Leussink, Leila Husseini, Clemens Warnke, Erasmia Broussalis, Hans-Peter Hartung, Bernd C. Kieseier |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2012-09-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285612453972 |
Similar Items
-
Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies
by: Verena I. Leussink, et al.
Published: (2016-07-01) -
Atacicept: targeting B cells in multiple sclerosis
by: Hans-Peter Hartung, et al.
Published: (2010-07-01) -
Cannabinoids control spasticity and tremor in a multiple sclerosis model.
by: Baker, D, et al.
Published: (2000) -
New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids
by: Paul F Smith
Published: (2010-02-01) -
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
by: Warnke C, et al.
Published: (2011-09-01)